Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease | Zendy

Lon S. Schneider | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease

Author(s) -

Lon S. Schneider

Publication year - 2011

Publication title -

archives of neurology

Language(s) - English

Resource type - Journals

eISSN - 1538-3687

pISSN - 0003-9942

DOI - 10.1001/archneurol.2011.69

Subject(s) - memantine , placebo , medicine , clinical trial , randomized controlled trial , confidence interval , dementia , alzheimer's disease , disease , clinical global impression , psychology , pathology , alternative medicine

We directly assessed the clinical trials' evidence for memantine's efficacy in mild Alzheimer disease (AD). Memantine is indicated in the United States and Europe for moderate to severe AD, which is diagnosed if a patient has a Mini-Mental State Examination (MMSE) score of less than 15 or less than 20, respectively. Yet memantine is very frequently prescribed for mild AD and mild cognitive impairment, and a manufacturer-sponsored meta-analysis claimed its efficacy in mild AD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research